Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMaria Sanchez-TaberneroAMAlejandro MedinaVGVerónica González‐Calle

Discussion

Loading...

Member takes

Overview

Validation study finds genomic alterations predict survival outcomes in newly diagnosed multiple myeloma, suggesting improved risk stratification.

Key Points

  • The research aimed to validate the Consensus Genomic Staging (CGS) system for high-risk multiple myeloma (HRMM).
  • Included 1,079 newly diagnosed multiple myeloma patients from four clinical trials.
  • Cytogenetic alterations assessed by FISH on plasma cells and TP53 mutations via next-generation sequencing.
  • Examined relationships between genomic alterations and patient outcomes.
  • High-risk genomic alterations identified in 26% of cases, with variances in risk classification compared to traditional criteria.
  • Median overall survival was lower in the CGS high-risk group compared to the standard-risk group (73% vs. 85%, p=0.022).
  • CGS high-risk status independently associated with worse overall and progression-free survival.

Cite This Study

Sanchez-Tabernero et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc9chttps://doi.org/10.1182/blood-2025-922
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.2026
  2. 2Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients2025 · 2 citations
  3. 3IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM2026 · 5 citations
  4. 4Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing2025
  5. 5Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.2025 · 2 citations